04 October 2019
Visiongain has published a new pharma report Top 50 Gastrointestinal Therapeutic Companies 2020: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.
The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.
This report profiled the selected companies: Abbott, AbbVie, Alexion Pharmaceuticals, Allergan, ANI Pharmaceuticals, Inc., AstraZeneca, Bayer AG, Biogen, Eisai Co., Ltd., Eli Lilly, Evoke Pharma, GlaxoSmithKline and other companies.
The lead analyst commented that "Emerging economies of Asia-Pacific and LAMEA possess high potential for gastrointestinal drugs. The rise in purchasing power in these economies is expected to augment the market growth. Rise in awareness regarding GI diseases such as, ulcerative colitis, IBD and cancer and the use of novel drugs the treatment of these diseases in the developing regions, have resulted in regulatory authorities in these regions to take key decisions to improve the legislations of gastrointestinal drugs."
Notes for Editors
f you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.